THOMAS ZINDRICK, JD
Executive Vice Chairman
Mr. Zindrick was elected to the position of Executive Vice Chairman at Aeromics in March 2019, and is responsible for strategic business operations at Aeromics. Mr. Zindrick brings over 25 years of executive experience in the life sciences and biotechnology and also currently serves as President & Chief Executive Officer of Genelux Corporation since 2014. Mr. Zindrick retired from Amgen, Inc. in 2009 after a distinguished 16-year career. While at Amgen, he held positions of increasing responsibility, including Vice President, Associate General Counsel and Chief Compliance Officer. As Vice President, Associate General Counsel, Mr. Zindrick led intellectual property, licensing and regulatory law teams and served on cross-functional business and product development teams. These teams were responsible for acquisitions totaling over $20 billion and the licensing and development of six therapeutic products and numerous clinical candidates. As Chief Compliance Officer, he reported to the Board of Directors and led the Corporate Compliance Program, which oversaw the compliance activities of numerous company functions including product development, manufacturing and marketing.
Chief Operating Officer
Mr. Thompson joined Aeromics as Chief Operating Officer after first serving Aeromics as a business development consultant through Pullan Consulting where he works with clients on their financing and partnering strategy execution. Prior to Pullan Consulting, Mr. Thompson was the VP of Corporate Development for Abeome, a small biotechnology company focused therapeutic antibodies and brings over 15 years of finance and operations experience to the role of COO for Aeromics.
MARC F. PELLETIER, MSC, PHD
Chief Scientific Officer
Dr. Pelletier co-founded Aeromics at Yale School of Medicine with Dr. Walter Boron, and served as Chief Executive Officer and Chief Scientific Officer from 2006 - 2019. He initiated Aeromics' drug discovery and development program, and as Chief Scientific Officer, continues to oversee strategic scientific operations. In 2015, he co-founded Iridia, Inc., a company developing the first molecular information storage technology (MIST) or DNA-based storage technology. Dr. Pelletier has over 27 years of experience in life sciences.
Anthony caggiano, md, PHD
Chief Medical Officer
Before joining Aeromics, Dr. Caggiano held he position of Vice President, Preclinical Development at Acorda Therapeutics. Dr. Caggiano managed Preclinical and Research & Development departments, as well as oversaw Acorda’s preclinical programs that aimed at developing novel approaches to the treatment of multiple sclerosis (MS), spinal cord injury (SCI) and stroke. Prior to joining Acorda,
Dr. Caggiano co-founded Remote Diagnostic Imaging, a company that assembled an expert staff of radiologists to provide remote diagnostic services to understaffed hospitals. Dr. Caggiano received his undergraduate degree in interdisciplinary studies of biology, chemistry and psychology from University of Virginia, and his M.D. and Ph.D. in neurobiology from the University of Chicago.
PAUL R MCGUIRK, PHD
Chief Technology Officer
Dr. McGuirk brings to Aeromics 27 years of pharmaceutical industry leadership experience. Prior to joining Aeromics, Paul as a principal medicinal chemist and Director of Infectious Diseases Medicinal Chemistry at Pfizer was responsible for leading the discovery and development of two marketed drugs: danofloxacin/Advocin® and trovafloxacin/Trovan®. He chaired the Allergy and Respiratory Early Clinical Management Team, solving numerous development challenges while progressing the inhaled PDEIV inhibitor tofimilast into Phase 2 studies. As Director Paul led the nearly 100 person interdisciplinary team that pioneered Pfizers’ADME/tox program. As Group Director of Chemical Technologies Paul co-led the large matrix multi-company team that helped build a successful 3 million compound HTS library. As Executive Director Dr. McGuirk led the global review and evaluation of 310 clinical candidates, over a 10-year period, as a prerequisite to their entry into formal development. The candidate reviews spanned 10 therapeutic areas and included several successful drugs such as Maraviroc®, Chantix®, and Zeljanz®. Paul is an expert on NCE attributes needed for success in drug development.
GEORGE FARR, PHD
Senior Research Scientist
Dr. Farr brings to Aeromics over 30 years of experience in biochemistry, biophysics and pharmacology. While at Case Western Reserve University, he discovered the eukaryotic cytosolic chaperonin and subsequently moved to Yale School of Medicine as an Associate Research Scientist in the Howard Hughes Medical Institute. At Yale Dr. Farr continued to elucidate the mechanism of chaperonin-assisted protein folding and investigated animal models of neurodegenerative disease where protein misfolding is the underlying cause.
board of directors
JEFFREY P. DRAIME
Mr. Draime has served as Aeromics’ Chairman since October 2017. Jeff is the son of D.M. Draime, the founder of Stoneridge, Inc. (NYSE: SRI) and has served in various roles with Stoneridge prior to serving as a member of their Board of Directors, a position he has held since 2004. He also currently holds positions on the Compensation, Nominating and Governance Committees. Mr. Draime provides independent business consulting services and serves as President of AeroMax Aviation Holdings, LLC.
THOMAS ZINDRICK, JD
Executive Vice Chairman, Director
PETER LONGO, CPA, CFA
Mr. Longo is the Senior Managing Director of Investments at Connecticut Innovations, Inc. (CI) and has spent over 23 years in numerous roles at CI. Mr. Longo is currently responsible for evaluating investment opportunities, structuring investments and monitoring portfolio companies through active board participation. Peter’s past CI investments include: Achillion Pharmaceuticals (IPO), Cardium Health (acquired by Centene), CYA Technologies (acquired by enChoice), eTouches (acquired by HGGC), NeuVis (acquired by Rational Software), Nufern (acquired by Rofin-Sinar), SilverSky (acquired by BAE Systems), PCC Technology Group (acquired by Clearview Capital) and Post-N-Track.
MARC F. PELLETIER, MSC, PHD
Chief Scientific Officer, Director
medical advisory board
JOSEPH SCHINDLER, MD
Dr. Schindler is a nationally recognized stroke expert and has served as a principal investigator on many clinical trials studying novel therapeutics for acute stroke and secondary prevention. Dr. Schindler serves as the Clinical Chief of the Division of Stroke and Vascular Neurology at Yale University School of Medicine where he is an Associate Professor of Neurology and of Neurosurgery. He serves as the Director of the Comprehensive Stroke Center at Yale-New Haven Hospital and is the founding Director of the Yale New-Haven Telestroke Service which has greatly extended access to stroke services throughout the state of Connecticut. Additionally, he is the Director of the Vascular Neurology Fellowship Program at Yale-New Haven Hospital & Yale University School of Medicine.
scientific advisory board
PETER AGRE, MD
Chief Scientific Officer, Emeritus; Co-Chairman
Dr. Agre is the Bloomberg Distinguished Professor at the Johns Hopkins Bloomberg School of Public Health and Johns Hopkins School of Medicine, and Director of the Johns Hopkins Malaria Research Institute. Dr. Agre served as President of the American Association for the Advancement of Science (2009-10). In 2003, Agre shared the Nobel Prize in Chemistry for his discovery of the Aquaporin water channels.
GEORGE FARR, PHD, co-chairman
Co-Chariman, Executive Vice President; Pharmacology
(see above, management team)
JACK REYNOLDS, DVM, DACLAM, DACVP, FIATP
Dr. Reynolds is a Founding Partner and the Executive Chairman of AnaBios Corporation. As an Aeromics Advisor, Jack was instrumental in providing oversight on pre-clinical safety of AER-271. Formerly Senior Vice President of Research and Development and Worldwide Head of Safety Sciences at Pfizer, Inc. he made substantial contributions including a new paradigm to elucidate, understand, manage and mitigate the inherent risks of medicines. This had a profound impact on Pfizer’s early stage portfolio in reducing attrition, improving drug development effectiveness and expanding their R&D portfolio. This early de-risking of drug development programs is only now being emulated by others.
ENRIQUE CARRAZANA, MD
Dr. Carrazana is the former Chief Medical Officer at Acorda Therapeutics and previously Global Head of the Development Franchise Established Medicines group at Novartis AG. He is a board-certified neurologist with more than 20 years of experience in the pharmaceutical industry and clinical practice and serves as a member of the Board of Directors at Marinus Pharmaceuticals. Dr. Carrazana received his M.D. from the Harvard Medical School and completed his residency in Neurology and fellowship in Neurophysiology at the Harvard Longwood Neurology Program.
BRUCE RANSOM, MD, PHD
Dr. Ransom is Professor and founding Chair of the Department of Neurology at the University of Washington (UW), where he also holds the Warren and Jermaine Magnuson Chair in Medicine for Neurosciences. He is adjunct Professor in the Department of Physiology and Biophysics, and a Research Affiliate of the Center on Human Development and Disability at UW. He is an expert in movement disorders and strokes that affect the white matter in the brain. Dr. Ransom is the founder and Editor-in-Chief of the journal GLIA. His research focuses on the physiology and function of astrocytes and the mechanisms of neural injury associated with ischemia, especially in axonal pathways of the brain. He is the co-author, with Helmut Kettenmann, of Neuroglia, a seminal textbook on glial cells.
PAUL PREDKI, PHD
Dr. Predki serves as Chief Technology Officer and Head of Research at Iridia, Inc. He was co-founder of Protometrix, a 2001 spin-out from Yale University. The company developed the first commercial protein microarray device and was acquired by Invitrogen in 2004. Invitrogen later became Life Technologies, where Dr. Predki served as Vice President R&D. He also served as Associate Director at the DOE Joint Genome Institute, where he was responsible for the development and implementation of the Institute’s high-throughput production sequencing and genomics programs. Dr. Predki also spent four years at CuraGen Corporation.